There are currently four IFN-β approved drugs for the treatment of relapsing forms of MS, three of which are administered subcutaneously (SC), IFNβ-1b, IFN-β-1a, and most recently peginterferon β-1a, one intramuscularly: IFN-β-1a (54). This evidence concerns the gene IFNB1 and myeloid sarcoma.